Study of Aspirin Low Molecular Weight Heparin Sodium and Rivashaban in the Prevention of Deep Venous Thrombosis of Lower Extremity after Knee Arthroplasty
MO Huagui, HUANG Yuanqiao, LUO Yuqiang, et al
Jiangmen Central Hospital, Guangdong Jiangmen 529030, China
Abstract：Objective: To investigate the preventive effect of aspirin, low molecular weight heparin sodium and rivashaban on deep venous thrombosis of lower extremity after knee arthroplasty. Methods: 200 patients with total knee replacement in our hospital from July 2017 to April 2019 were selected as the subject of the study.The patients with the group A were given an oral rivasahan treatment, and the povtients in group B was given an oral aspirin, and the group C was given low molecular heparin sodium injection treatment. The prothrombin time (PT), activated partial thromboplastin time (APTT), D-dimer) and platelet value (Plt) were observed and compared among the three groups, and the incidence of deep venous thrombosis of lower extremity was recorded. Results: After anticoagulation, the number of effective treatment cases in group A (66 cases) was significantly higher than that in group B (44 cases, 68.75%) and group C (47 cases, 71.21%). The total effective treatment rate was 94.29%, with a significant difference (P<0.05); There was no significant difference in Pt, APTT and PLT indexes between group A and group B (P>0.05), and there was significant difference in three indexes between group A and group C (P<0.05); One day, one week and 15 days after the treatment, the D-dimer value of group A was significantly lower than that of group B (P<0.05); one week and 15 days after the treatment, the D-dimer value of group A was significantly lower than that of group C (P<0.05); two patients in group A had DVT, the incidence was 5.88%; six patients in group B, the incidence was 17.65%; ten patients in group C, the incidence was 29.4%. There was no significant difference between the two groups (χ2 = 2.267, P = 0.132) and the two groups (DVT χ2=1.308, P=0.253,P=0.253, P<0.05). Conclusion: Compared with low molecular weight heparin, aspirin has a higher therapeutic safety, but a lower therapeutic effect; rivaroxaban has a higher anticoagulant effect, but a higher incidence of occult blood loss and incision complications. Therefore, the anticoagulation needs of patients can be reasonably selected according to the actual situation.
莫华贵, 黄远翘, 罗裕强, 马滚韶, 邬黎平, 徐勤, 张荣凯. 阿司匹林低分子肝素钠利伐沙班预防膝关节置换术后下肢深静脉血栓形成研究[J]. 河北医学, 2020, 26(4): 533-537.
MO Huagui, HUANG Yuanqiao, LUO Yuqiang, et al. Study of Aspirin Low Molecular Weight Heparin Sodium and Rivashaban in the Prevention of Deep Venous Thrombosis of Lower Extremity after Knee Arthroplasty. HeBei Med, 2020, 26(4): 533-537.
[1] Kamil Hanna,Aizaz Khalid,Mohammad Hamidi,et al. Chronic alcohol consumption and risk of deep venous thrombosis: a propensity-matched analysis[J]. Journal of Surgical Research,2019,244(2):251~256. [2] Takashi Hirata,Kazuyuki Yasuda,et al. Electroconvulsive therapy while receiving oral anticoagulation for deep venous thrombosis:report on eight cases and a review of the literature[J]. Psychosomatics,2019,60(4):402~409. [3] 尚春风,寇红伟,张书豪,等.中老年人腰椎退变性疾病术后早期下肢深静脉血栓形成的相关因素[J].郑州大学学报(医学版),2019,54(3):477~480. [4] 杜飞.利伐沙班与低分子肝素钠治疗人工膝关节置换术后并发下肢深静脉血栓的疗效对比[J].中国现代药物应用,2019,13(3):134~136. [5] 陈寅钦,王山林,黄德铨.低分子肝素和利伐沙班对髋膝关节置换术后深静脉血栓的预防效果探讨[J].中国医药科学,2019,9(2):71~73. [6] 王永刚,史振宇,符伟国,等.利伐沙班和低分子肝素用于部分实体恶性肿瘤合并静脉血栓栓塞症抗凝的疗效分析[J].复旦学报(医学版),2018,45(1):57~61. [7] 邵素臣,俞昌明.彩色多普勒超声在下肢深静脉血栓诊断中的临床应用[J].医学影像学杂志,2017,27(4):783~786. [8] 蒋家斌,于涛.阿司匹林对于初次人工膝关节置换术后失血量的影响[J].中国实验诊断学,2017,21(1):111~112. [9] 李炳林,章莹.阿司匹林或利伐沙班对髋膝关节置换术后VTE的预防效果[J].中国骨科临床与基础研究杂志,2018,10(2):122. [10] 李宁,罗汉文,涂泽松,等.不同剂量利伐沙班防治全髋关节置换术后深静脉血栓形成的效果比较[J].海南医学,2017,27(8):1250~1253. [11] 董文铭,肖彦燊,李志丹,等.低分子肝素钠与利伐沙班对全膝关节置换术后隐性失血的影响比较[J].广东医科大学学报,2018,36(6):664~668.
2020, Vol. 26 
冀公网安备13080202000677号